comprehensive -WSS

comprehensive

author：fashion 2025-09-27 13:10:33 - browse：1

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Medicare inequities exacerbate Puerto Rico’s health disparities

explore

WSS

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Why palliative psychiatry is worth discussing

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Dario to buy mental health app maker Twill in cash and stock deal

Pharma companies must ensure equitable access to obesity drugs

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare details structure of new drug price negotiation program

My daughter's legacy lives on through her writing, phage therapy

Affirmative action in medical school literally saved lives

Moderna says combo Covid

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare inequities exacerbate Puerto Rico’s health disparities

Hepatitis C has a cure — but many Americans still lack access to it

STAT Virtual Event: ASCO Recap, Live!

Sports medicine is finally prioritizing gender equality

Pharma companies must ensure equitable access to obesity drugs

focus

Why palliative psychiatry is worth discussing

STAT Virtual Event: ASCO Recap, Live!

The Harvard botanist who searched for psychedelics in the Amazon

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

In utero gene editing: an explainer

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

leisure time

focus

explore

focus